It is with great pleasure that we provide this commentary with a focus on influenza vaccination for an expert consensus entitled "Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China" to be published in this issue of Aging Medicine. 1 Influenza is a major global public health burden with pandemic threat. Seasonal influenza infection is responsible for 3-5 million severe illness cases and 290 000-650 000 respiratory deaths annually worldwide. 2, 3 According to the Centers for Disease Control and Prevention (CDC), influenza affects 5%-20% of the population each year in the United States. 4 It is estimated that influenza causes 226 000 excess hospitalizations, 25 000-69 000 deaths, and US $87 billion excess health-care cost with over 600 000 life-years lost annually. 5, 6 Among all infectious diseases, influenza is foremost in its age-related increase in serious complications, leading to hospitalization, catastrophic disability, and death in older adults. 7, 8 Moreover, influenza frequently causes exacerbation of many chronic conditions that are common in older adults, including cardiovascular diseases, 9, 10 further indirectly impacting senior health and mortality. In fact, over 90% of influenza-related mortality occurs in persons aged over 65 years. 11 In the United States, influenza and its secondary pneumonia are the fourth leading cause of death in this population. 12 Therefore, prevention and treatment of influenza in older adults have become a major public health priority.
Like many preventable infectious diseases, immunization is the main strategy for influenza prevention in addition to the universal contact-and airborne-precaution measures. In the United States, annual influenza vaccination is recommended for all adults aged 50 years and older. The annual vaccination is overall efficacious, with estimated risk reduction of 50%-70% for influenza infection in young adults and less robust risk reduction in older adults. 13, 14 This reduced efficacy in older adults is thought to be due to immunosenescence and common health conditions, such as frailty. 15 In recent years, a new generation of influenza vaccines, including high-dose (HD) and adjuvanted ones, have been approved by the US Food and Drug Administration (FDA) for older adults in the United States and elsewhere, in addition to the standard dose trivalent inactivated influenza vaccine (IIV3).
As Chen et al 1 point out in the expert consensus paper, influenza vaccination coverage for older adults in China is extremely low. This is in the context of the largest and fastest growing older adult population, 16 There are a number of other reasons for extremely low influenza should also be considered before these vaccines can be produced domestically with quality assurance. This pillar is particularly important to reestablish public confidence since the recent vaccine scandals stated above.
Last but not least is the pillar of innovation and research. After all, it is the effort of innovation and research that has led to the development and FDA-approved clinical application of the new generation of influenza vaccines described above. In China, the pillar of innovation and research will need to be built from the ground up with special consideration of the following three aspects.
1. There is an urgent need to establish a comprehensive, nationwide influenza surveillance mechanism or network to monitor and report influenza epidemic activity with laboratory diagnosis of influenza infection and confirmation of specific virus strain for each influenza season across China. Such an influenza surveillance mechanism/network will provide important, real-time information about influenza epidemic activities across different Other entities can directly play a role in education and innovation and research (green solid lines) and vaccine development and supply (green dotted arrow). Working together, it is hoped that these key players along with the public will improve policy, education, vaccine supply, as well as innovation and research, ultimately leading to universal influenza vaccination coverage for seniors and those who need vaccine protection in China.
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